IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (OTCBB:CORX) announced that Mark A. Varney, Ph.D., President and CEO, will speak at the 23rd Annual Roth Capital Partners Growth Stock Conference to be held at The Ritz-Carlton, Laguna Niguel hotel located in Dana Point, California. Dr. Varney will present on Wednesday, March 16, 2011, at 1:00 pm PST (4:00 pm EST). The conference will feature executives from over 400 growth companies across a broad spectrum of sectors, including energy, software, technology, healthcare, media and consumer products. Dr. Varney will provide an update on Cortex’s 2011 corporate objectives and milestones, including recent progress on its lead Ampakine® clinical compound, CX1739, as a novel drug therapy for sleep apnea and ADHD, along with other scientific and corporate developments. A live webcast of the presentation can be accessed by logging onto http://www.wsw.com/webcast/roth24/cor/. A replay will be available for thirty days following the conference. More information regarding the conference can be found at the link to the Roth conference website, http://www.roth.com/main/page.aspx?PageID=7236.
Cortex Pharmaceuticals, Inc.
Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for treating psychiatric disorders, neurological diseases and sleep apnea. Cortex is pioneering a class of proprietary pharmaceuticals called Ampakine® compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain’s neurotransmitter system. These imbalances may be improved by using the Ampakine technology. For additional information regarding Cortex, please visit the Company’s website at http://www.cortexpharm.com.
Forward-Looking Statement
Note — this press release contains forward-looking statements concerning the Company’s operating activities. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward-looking statements. These statements are based on the Company’s current beliefs and expectations. The success of such activities depends on a number of factors, including the risks that the Company’s drug candidates may at any time be found to be unsafe or ineffective for their intended use, including the treatment of sleep apnea, ADHD, schizophrenia, depression, or Parkinson’s disease; or that the Company may have insufficient resources to undertake proposed clinical studies and that preclinical or clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company’s Securities and Exchange Commission filings, the Company’s proposed products will require additional research, lengthy and costly preclinical and clinical testing and regulatory approval. Ampakine compounds are investigational drugs and have not been approved for the treatment of any disease. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this press release. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.